• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Medical Journal of Viral Hepatitis
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 9.1 (2025)
Volume Volume 8.2 (2024)
Volume Volume 8.1 (2024)
Volume Volume 7.3 (2023)
Volume Volume 7.2 (2023)
Volume Volume 7.1 (2022)
Volume Volume 6.3 (2022)
Volume Volume 6.2 (2022)
Volume Volume 6.1 (2021)
Volume Volume 5.3 (2021)
Volume Volume 5.2 (2021)
Volume Volume 5.1 (2020)
Volume Volume 4.2 (2020)
Volume Volume 4.1 (2019)
Volume Volume 3.2 (2019)
Volume Volume 3.1 (2018)
Volume Volume 2.2 (2018)
Volume Volume 2.1 (2016)
Issue Issue 1
Volume Volume 1.2 (2016)
Volume Volume 1.1 (2015)
R., S., G., S., M., E., H., M. (2016). The 13C-Aminopyrine Breath Test Predicts Advanced Fibrosis in Patients with Chronic Hepatitis C: A Pilot Study. Medical Journal of Viral Hepatitis, 2.1(1), 1-8. doi: 10.21608/mjvh.2016.4570
Soliman R.; Shiha G.; El-Basiouny M.; Mikhail H.. "The 13C-Aminopyrine Breath Test Predicts Advanced Fibrosis in Patients with Chronic Hepatitis C: A Pilot Study". Medical Journal of Viral Hepatitis, 2.1, 1, 2016, 1-8. doi: 10.21608/mjvh.2016.4570
R., S., G., S., M., E., H., M. (2016). 'The 13C-Aminopyrine Breath Test Predicts Advanced Fibrosis in Patients with Chronic Hepatitis C: A Pilot Study', Medical Journal of Viral Hepatitis, 2.1(1), pp. 1-8. doi: 10.21608/mjvh.2016.4570
R., S., G., S., M., E., H., M. The 13C-Aminopyrine Breath Test Predicts Advanced Fibrosis in Patients with Chronic Hepatitis C: A Pilot Study. Medical Journal of Viral Hepatitis, 2016; 2.1(1): 1-8. doi: 10.21608/mjvh.2016.4570

The 13C-Aminopyrine Breath Test Predicts Advanced Fibrosis in Patients with Chronic Hepatitis C: A Pilot Study

Article 2, Volume 2.1, Issue 1, November 2016, Page 1-8  XML PDF (170.91 K)
Document Type: Original article
DOI: 10.21608/mjvh.2016.4570
View on SCiNiTO View on SCiNiTO
Authors
Soliman R.1; Shiha G.2; El-Basiouny M.2; Mikhail H.3
1Egyptian Liver Research Institute and Hospital (ELRIH), Sherbin, El-Mansoura, Egypt
2Egyptian Liver Research Institute and Hospital (ELRIH), Sherbin, El-Mansoura, Egypt, Hepatology & Gastroenterology unit, Internal Medicine Department, Faculty of Medicine,El-Mansoura University, Egypt
3Egyptian Liver Research Institute and Hospital (ELRIH), Sherbin, El-Mansoura, Egypt,Department of Biostatistics, South Egypt Cancer Institute, Assiut University, Egypt
Abstract
13C Aminopyrine breath test (13C-ABT) is a dynamic function test based on the use of a labelled substrate that selectively metabolized by the liver which is useful in the evaluation of hepatocyte function providing a quantitative information on liver function activity. A significant inverse correlation between C13-ABT results and liver fibrosis was found. In this study we investigate the accuracy of 13C-ABT as non-invasive method for identification of liver fibrosis compared to other non-invasive methods. Thirty-six chronic hepatitis C patients were recruited from the outpatient clinic of the Egyptian
Liver Research Institute and Hospital (ELRIAH). Percutaneous liver biopsy and routine blood sampling were performed at the same day. FibroScan and 13C-ABT were done. Liver fibrosis showed strong correlation with FibroScan (r=0.717, p<0.001) and significant inverse correlation with 13C-ABT results, especially at 30 min. (r= -0.371, p=0.026). Significant correlation was found with FIB-4 (r=0.350, p=0.039) and not significant correlation was found with APRI (r=0.261, p=0.240). The cut-off value of 3.15% (dose/hr at 30 min) was associated with high prediction (positive predictive value, 60%; negative predictive value, 92.3%) yielding an overall sensitivity of 75% and specificity of 85.7%. As regards the 13C-ABT % cum. dose at 120 min, a cut-off value of 4.35 was also associated with high accuracy (PPV=47.1%, NPV=100%, Sensitivity=100% and Specificity=67.9%. These results of high accuracy is comparable to FibroScan and FIB-4, and is better than the results of APRI. 13C-aminopyrine breath test is a potential biomarker for advanced fibrosis
that warrants further validation. 
Keywords
13C-Aminopyrine Breath; test; Chronic hepatitis C; FibroScan; FIB-4; APRI
Statistics
Article View: 384
PDF Download: 635
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.